Aurinia Pharmaceuticals Inc. AUPH 深 沪
等待开盘 08-25 09:30:00 美东时间
16.57
-0.080
-0.48%
华盛通- 最 高16.68
- 今 开16.57
- 成交量 68.63万股
- 最 低 16.3085
- 昨 收 16.65
- 总市值 22.05亿
- 52周最高 19.25
- 市盈率 静 8.00
- 换手率 0.00%
- 52周最低 10.34
- 委 比 45.73%
- 总股本 1.33亿
- 历史最高 33.972
- 量 比 0.47
- 振 幅 2.23%
- 历史最低 1.41
- 每 手 1
- 风险率 1.54%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多Aurinia settles Lupkynis patent litigation with Teva
Teva Pharmaceutical Industries (TEVA) will not be able to launch a generic version of Aurinia Pharmaceuticals' (AUPH) Lupkynis (voclosporin) until Dec. 7, 2036, at the earliest under a settlement. Tev...
08-20 05:12
Aurinia Settles Teva Patent Litigation, Protecting Voclosporin Exclusivity In U.S. Until December 2036 And Affirming Validity Of Key Patents Through 2037
Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH) today announced that it and its subsidiary, Aurinia Pharma U.S., Inc., (collectively, "Aurinia") have entered into a settlement agreement with Teva Pharmaceuticals Inc. ("Teva") to resolve patent infringement litigation relating to Teva’s filing of an Abbre...
08-20 04:07
美股大行评级 | 花旗下调美光科技目标价从1400美元降至1150美元；爱彼迎、Datadog、Cloudflare、Etsy、Natera、拉夫劳伦获多家大行上调目标价
今日重点评级关注：康托·菲茨杰拉德：维持InflaRx"超配"评级，目标价从4美元升至6美元；RBC Capital：维持Nuvation Bio"跑赢大市"评级，目标价从19美元升至20美元
08-10 19:24
Aurinia Pharmaceuticals Affirms FY2026 Sales Guidance of $315.000M-$325.000M vs $323.065M Est
Aurinia Pharmaceuticals (NASDAQ:AUPH) affirms FY2026 sales outlook from $315.000 million-$325.000 million to $315.000 million-$325.000 million vs $323.065 million estimate.
08-06 20:41
Aurinia Pharmaceuticals Q2 EPS $0.28 Beats $0.24 Estimate, Sales $83.220M Beat $79.357M Estimate
Aurinia Pharmaceuticals (NASDAQ:AUPH) reported quarterly earnings of $0.28 per share which beat the analyst consensus estimate of $0.24 by 16.67 percent. This is a 75 percent increase over earnings of $0.16 per share from the same period last year. The company reported quarterly sales of $83.220 mil...
08-06 20:40
Aurinia Targets Myasthenia Gravis With New Aritinercept Trial, Expanding Its Growth Story
Aurinia Pharmaceuticals ($AUPH) announced an update on their ongoing clinical s...
08-04 00:32
Zacks行业展望：Indivior、Aurinia、Ironwood、Altimmune及Marker
2026年6月26日，扎克斯股票研究聚焦5只小型制药标的：Indivior制药（INDV）、Aurinia制药（AUPH）、Ironwood制药（IRWD）、...
06-26 18:07
Aurinia’s PRESERVE Trial: New Combination Strategy for Lupus Nephritis in Focus
Aurinia Pharmaceuticals ($AUPH) announced an update on their ongoing clinical s...
06-13 00:34
Lupkynis新分析：显著降低狼疮性肾炎患者肾脏事件或死亡风险53%
Aurinia Pharmaceuticals公司近日在欧洲风湿病学协会联盟2026年大会上公布了一项关于Lupkynis治疗狼疮性肾炎的最新分析结果。数据...
06-04 23:55
Lupkynis新分析：显著降低狼疮性肾炎患者肾脏事件或死亡风险53%
Aurinia Pharmaceuticals公司近日在欧洲风湿病学协会联盟2026年大会上公布了一项关于Lupkynis治疗狼疮性肾炎的最新分析结果。数据...
06-04 23:55
